Is Global Health overvalued or undervalued?

As of 14 November 2025, the valuation grade for Global Health has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 52.58, an EV to EBITDA of 32.56, and a PEG ratio of 2.31, which indicate a premium valuation compared to its peers.
In comparison, Apollo Hospitals, rated as attractive, has a PE ratio of 63.77 and an EV to EBITDA of 33.53, while Narayana Hrudaya, categorized as expensive, has a PE ratio of 45.39 and an EV to EBITDA of 28.01. These comparisons highlight that Global Health's valuation is higher than some of its peers, suggesting that the stock may not be justified at its current price of 1,173.10, especially given its recent underperformance relative to the Sensex over the past month.